Neonatal herpes simplex virus infections: pathogenesis and therapy.
Neonatal herpes simplex virus (HSV) infections are of increasing incidence in North America, now occurring at a rate of approximately one in 3,500 to one in 5,000 deliveries per year. Disease manifests as one of three forms; namely, infection: localized to the skin, eye and mouth (SEM), encephalitis (CNS), or disseminated disease. With the advent of antiviral therapy, it has become possible to decrease mortality and improve morbidity for babies suffering from infection. Advances in antiviral therapy have allowed for prevention of disease progression beyond states of SEM involvement. Furthermore, life threatening infections of the CNS or of multiple organs, have mortality with either acyclovir or vidarabine therapy. Now approximately 15% (CNS) and 50% (disseminated disease) of babies die from neonatal HSV disease. The results of ongoing studies in the United States will summarize the pathogenesis and treatment of neonatal HSV infection.
Whitley
R J
RJ
School of Medicine, Department of Pediatrics, University of Alabama, Birmingham 35294-0011.
D000212:Acyclovir / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004660:Encephalitis / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D006801:Humans; D007231:Infant, Newborn; D009422:Nervous System Diseases / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality; D011247:Pregnancy; D018139:Simplexvirus / Q000302:isolation & purification / Q000472:pathogenicity*; D014740:Vidarabine / Q000627:therapeutic use*
D014740:Vidarabine; D000212:Acyclovir